Study study type PathologyT1T0Patientssample sizesROB Results

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
NeoTRIPaPDLA unpublished
  NCT02620280
RCTes-BC - TNBC - NA - all populationatezolizumab plus carboplatine plus nab-paclitaxelcarboplatine plus nab-paclitaxelNeoadjuvant Therapy in TRIPle Negative Breast Cancer (early or locally advanced)88 / 86NA
inconclusive
    no statistically significant result
versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
IMpassion-031 (all population), 2020
  NCT03197935
RCTes-BC - TNBC - NA - all populationAtezolizumab plus nab-paclitaxel followed by doxorubicin and cyclophosphamide with filgrastim or pegfilgrastim supportplacebo plus nab-paclitaxel followed by doxorubicin and cyclophosphamide with filgrastim or pegfilgrastim supportneoadjuvant setting in participants with early stage (stage II-III) triple negative breast cancer165 / 168low
conclusif
  • demonstrated 95 % increase in pCR (PE)